Camlin Fine Sciences Limited

BSE: 532834 NSE: CAMLINFINE
Camlin Fine Sciences Limited - chemicals and materials in Mumbai, Maharashtra, India. FY 2026 financials & compliance.
CIN L74100MH1993PLC075361 Incorporated 30 November 1993 ROC Mumbai HQ Mumbai, Maharashtra, India
Active Listed - NSE: CAMLINFINE · BSE: 532834 Public Limited Company chemicals and materials
Data last updated
Market Cap
₹1,581 Cr
CAMLINFINE · NSE
Share Price
₹84.10
+2.16% today
Revenue
₹1,723 Cr
FY 2025-26 · +5.8% YoY
EBITDA
₹91.39 Cr
Margin 5.3%
Net Profit
₹36.46 Cr
FY 2025-26 · +127.8% YoY
ROE
3.3%
ROCE 4.7%
Debt / Equity
0.71
Interest cover 404.9x
Authorised capital
₹25 Cr
Registered with MCA

About Camlin Fine Sciences Limited

Data last updated:

Camlin Fine Sciences Limited is a public limited company based in Mumbai, Maharashtra, India. It operates in the specialty chemicals segment of the chemicals and materials sector. It was incorporated on 30 November 1993 and has been in existence for over 33 years.

The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN L74100MH1993PLC075361. Its GSTIN is 27AACCC5235E1ZZ (Maharashtra). The company holds 4 GST registrations, of which 3 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 532834 and NSE: CAMLINFINE.

The company has an authorised share capital of ₹25 Cr and a paid-up capital of ₹19.21 Cr. It was formerly known as Camlicon Consultants Private Limited and Camlin Fine Chemicals Private Limited. It is led by directors including Ashish Subhash Dandekar (Managing Director) and Nirmal Vinod Momaya (Managing Director).

Its last annual general meeting (AGM) was held on 08 August 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Mumbai, Maharashtra.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹1,723.31 Cr, a growth of 5.8% compared to the previous year. For the same year it recorded a net profit of ₹36.46 Cr (net margin 2.1%) and EBITDA of ₹91.39 Cr (EBITDA margin 5.3%). The net worth stands at ₹1,040.88 Cr (up 15.4% YoY). Total assets are valued at ₹1,728.66 Cr (up 12.8% YoY).

The company has about 612 employees on its provident fund (EPFO) records. Its group structure includes 2 subsidiaries.

The company is associated with 1 brand: Camlin Fine Sciences. As per MCA filings, the company has open charges of ₹636.6 Cr and satisfied charges of ₹1,187.59 Cr on record. Court records list 27 cases involving the company, including 14 filed by the company and 13 filed against it; 8 cases are pending. The company has 48 deals on record (35 market trades, 6 secondary share transfers, 4 funding rounds), with disclosed funding of ₹282.67 Cr; the latest was in April 2026. Its 7 peer companies in the Chemicals industry (Specialty Chemicals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 3 larger and 4 smaller; the largest is Kutch Chemical Industries Limited with revenue of ₹1,985.16 Cr. The company has 17 MSME Form 1 returns on record between 2019 and 2024, listing 1,880 overdue payments to 341 micro and small suppliers.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website camlinfs.com.

Company details

CIN L74100MH1993PLC075361
Registration Number 075361
Incorporation Date 30 November 1993
ROC Mumbai
Listing Status Listed - Listed on NSE (CAMLINFINE); Listed on BSE (532834)
Company Status Active
Date of Last AGM 08 August 2025
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant

Name history

Camlin Fine Sciences has undergone 3 name changes throughout its history. The company was previously known as Camlicon Consultants Private Limited, Camlin Fine Chemicals Private Limited, and Camlin Fine Chemicals Limited. The current legal name is Camlin Fine Sciences Limited.

Company NameStatus
Camlin Fine Sciences LimitedCurrent
Camlicon Consultants Private LimitedPrevious
Camlin Fine Chemicals Private LimitedPrevious
Camlin Fine Chemicals LimitedPrevious

CIN history

Camlin Fine Sciences has one previous CIN (Corporate Identification Number): U74100MH1993PLC075361. The current CIN is L74100MH1993PLC075361, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L74100MH1993PLC075361Current
U74100MH1993PLC075361Previous
Key People
Ashish Subhash Dandekar Managing Director Nirmal Vinod Momaya Managing Director Arjun Sudhakar Dukane Whole-Time Director

Contact details

Camlin Fine Sciences Limited's registered office is in Mumbai, Maharashtra. Its website is camlinfs.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
    camlinfs.com
  • Social Media
  • Registered Address
    In G.S. Point Plot No. VIII C.S.T. Road Private Layout Scheme Kalina Santacruz, East, Mumbai, Maharashtra, India – 400098
  • Industry
    Chemicals and Materials, Specialty Chemicals

To see the full contact details of Camlin Fine Sciences Limited, buy the company report.

Comprehensive company report
Camlin Fine Sciences Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Camlin Fine Sciences operates one associated brand: Camlin Fine Sciences. Each brand links to its own profile.

BrandDescriptionWebsite
Camlin Fine Sciences
Manufacturer of fine chemicals catering to food industrycamlinfs.com

Business activity

The main business activity of Camlin Fine Sciences is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
CManufacturingC6Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products

To see the full business activity and turnover split of Camlin Fine Sciences Limited, buy the company report.

Financials of Camlin Fine Sciences Limited

FY 2025-26 filings available

Camlin Fine Sciences Limited reported revenue of ₹1,723.31 Cr (up 5.8% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹1,723 Cr
+5.8% YoY
EBITDA
₹91.39 Cr
+1486.8% YoY
Profit After Tax
₹36.46 Cr
+127.8% YoY
Net Worth
₹1,041 Cr
+15.4% YoY
Total Assets
₹1,729 Cr
+12.8% YoY
Total Debt
₹720 Cr
+10.5% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue1,7231,6291,4541,6821,4121,1871,049
Revenue growth+5.8%+12.0%-13.5%+19.1%+19.0%+13.2%-
EBITDA91.39(6.59)11.52201158187135
EBITDA margin+5.3%-0.4%+0.8%+12.0%+11.2%+15.7%+12.9%
Profit before tax23.11(159)(99.24)80.3893.9710558.21
Net profit36.46(131)(92.64)56.9460.8350.9530.33
Net profit margin+2.1%-8.1%-6.4%+3.4%+4.3%+4.3%+2.9%
EPS (₹)1.44(7.40)(5.54)3.323.874.002.50
Balance sheet
Total assets1,7291,5331,5461,6301,4361,2661,001
Net worth1,041902865819748643403
Total debt720652683801646550539
Cash & bank15315493.5399.2314213864.79
Net working capital643658602673540585444
Cash flow
Cash from operations82.0723.0013950.9014511786.02
Cash from investing(52.95)(75.35)(66.50)(125)(249)(133)(90.12)
Cash from financing(24.63)76.17(85.97)59.6613638.633.25
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue520425441460408432431417
Revenue growth (YoY)+27.5%-1.6%+2.2%+10.2%+7.1%---
Other income2.741112.684.597.5212.971.3411.81
EBITDA(3.66)13.24(6.30)24.1112.7626.9046.88(111)
EBITDA margin-0.7%+3.1%-1.4%+5.2%+3.1%+6.2%+10.9%-26.7%
Depreciation19.1620.8216.3218.8316.1317.1414.4816.51
Interest14.0122.9817.2618.9114.8614.9334.0726.32
Profit before tax(34.09)80.04(37.20)(9.04)(10.71)7.80(0.33)(142)
Tax(0.46)(6.24)(0.09)5.91(0.02)7.697.14(26.20)
Net profit(33.63)86.28(37.11)(14.95)(10.69)0.11(7.47)(116)
EPS (₹)(1.65)4.54(2.38)(0.76)(0.53)(1.24)(0.71)(5.83)
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue838886773789686600580
Revenue growth-5.5%+14.6%-2.1%+15.2%+14.2%+3.5%-
EBITDA39.74(16.41)32.7213380.4465.2059.83
EBITDA margin+4.7%-1.9%+4.2%+16.9%+11.7%+10.9%+10.3%
Profit before tax(54.09)(123)(59.64)66.6236.0715.0341.28
Net profit(15.42)18.41(49.07)47.7325.868.5533.10
Net profit margin-1.8%+2.1%-6.4%+6.1%+3.8%+1.4%+5.7%
EPS (₹)(1.72)(4.06)(3.07)3.031.650.652.53
Balance sheet
Total assets1,4181,2961,2321,2641,056846721
Net worth929862716642592465377
Total debt482428511617461378340
Cash & bank80.8984.6513.959.8356.4881.5913.12
Net working capital565558527561441444342
Cash flow
Cash from operations43.9618.1482.1018.5246.8026.0273.90
Cash from investing(30.40)(87.66)(51.72)(115)(172)(88.00)(66.03)
Cash from financing(13.41)105(34.05)78.3912980.05(26.06)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue222184219244191273205227
Revenue growth (YoY)+16.2%-32.7%+6.8%+7.6%+5.2%---
Other income1.4015.305.7710.193.699.206.823.08
Total expenses216180214226187239189309
EBITDA6.823.405.3418.204.6833.2716.39(82.26)
EBITDA margin+3.1%+1.9%+2.4%+7.5%+2.4%+12.2%+8.0%-36.3%
Depreciation13.5113.2913.5113.4713.4013.1313.2613.44
Interest13.3822.0514.8618.7311.3417.4417.1517.92
Profit before tax(18.67)(16.64)(17.26)(3.81)(16.37)11.90(7.20)(111)
Tax(6.36)(10.99)(4.27)(0.17)(5.70)(3.72)(1.57)(37.92)

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 31 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue520425441460408432431417
Revenue growth (YoY)+27.5%-1.6%+2.2%+10.2%+7.1%---
Other income2.741112.684.597.5212.971.3411.81
EBITDA(3.66)13.24(6.30)24.1112.7626.9046.88(111)
EBITDA margin-0.7%+3.1%-1.4%+5.2%+3.1%+6.2%+10.9%-26.7%
Depreciation19.1620.8216.3218.8316.1317.1414.4816.51
Interest14.0122.9817.2618.9114.8614.9334.0726.32
Profit before tax(34.09)80.04(37.20)(9.04)(10.71)7.80(0.33)(142)
Tax(0.46)(6.24)(0.09)5.91(0.02)7.697.14(26.20)
Net profit(33.63)86.28(37.11)(14.95)(10.69)0.11(7.47)(116)
EPS (₹)(1.65)4.54(2.38)(0.76)(0.53)(1.24)(0.71)(5.83)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue1,7231,6291,4541,6821,4121,1871,049
Revenue growth+5.8%+12.0%-13.5%+19.1%+19.0%+13.2%-
Other income85.5315.6015.555.8033.034.983.43
Total expenses1,6321,6351,4421,4801,2541,000914
Employee cost24418515316314512099.71
EBITDA91.39(6.59)11.52201158187135
EBITDA margin+5.3%-0.4%+0.8%+12.0%+11.2%+15.7%+12.9%
Depreciation70.9260.9656.3562.5155.9644.2932.80
Interest82.8910769.9664.1840.8042.4847.63
Profit before tax23.11(159)(99.24)80.3893.9710558.21
Tax(0.46)(0.51)5.6340.5733.6039.7428.37
Net profit36.46(131)(92.64)56.9460.8350.9530.33
Net profit margin+2.1%-8.1%-6.4%+3.4%+4.3%+4.3%+2.9%
EPS (₹)1.44(7.40)(5.54)3.323.874.002.50
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital19.2118.7916.7515.7115.7012.7512.13
Reserves & surplus1,018880845800729582388
Shareholders' funds (net worth)1,041902865819748643403
Minority interest(40.07)(26.89)(7.80)4.7117.1269.7556.97
Secured loans624529520613411283326
Unsecured loans96.00122163188235267213
Total debt720652683801646550539
Total liabilities1,7291,5331,5461,6301,4361,2661,001
Assets
Gross block1,3271,2711,1691,124816753430
Net block887704816858601584306
Capital work in progress32.859.7345.8743.0221523.82179
Investments30.2660.987.887.967.237.367.36
Inventories504527540568371320298
Sundry debtors373328285305300271253
Cash & bank balances15315493.5399.2314213864.79
Loans & advances20413610911680.8765.6559.21
Total current assets1,2341,1451,0281,088894795675
Total current liabilities591488426415354209230
Net working capital643658602673540585444
Total assets1,7291,5331,5461,6301,4361,2661,001
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash10480.2593.7410875.5252.3753.21
Net cash from operating activities82.0723.0013950.9014511786.02
Net cash from investing activities(52.95)(75.35)(66.50)(125)(249)(133)(90.12)
Net cash from financing activities(24.63)76.17(85.97)59.6613638.633.25
Net change in cash4.4823.82(13.49)(14.07)32.2923.15(0.85)
Closing cash15315493.5399.2314213864.79
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+5.8%+12.0%-13.5%+19.1%+19.0%+13.2%-
EBITDA growth+1486.8%-157.2%-94.3%+27.6%-15.6%+38.2%-
PBT growth+9998.0%-59.8%--14.5%-10.6%+80.6%+248.6%
Net income growth+127.8%-41.7%-262.7%-6.4%+19.4%+68.0%-
Revenue CAGR (3Y)+0.8%+4.9%+7.0%+17.0%+16.5%+18.1%+25.3%
EBITDA CAGR (3Y)-23.1%--60.5%+14.2%+29.4%+126.9%+61.9%
Profitability & leverage
Net income margin+1.4%-9.7%-7.2%+2.4%+4.3%+5.5%+2.8%
Return on capital employed+4.7%+11.9%+8.4%+10.7%+11.1%+14.5%+11.9%
Return on net worth+3.3%-17.5%-13.3%+6.3%+10.0%+13.8%+7.7%
Debt / equity0.710.780.941.020.991.151.29
Long-term debt / equity0.320.370.490.580.570.530.54
Interest cover404.93-157.93-156.0646.2540.1029.7946.51
Efficiency & per share
Fixed asset turnover1.331.361.331.872.042.192.66
Inventory turnover3.343.052.623.584.093.843.60
Debtors turnover4.925.314.935.574.954.544.54
EPS (₹)1.44(7.40)(5.54)3.323.874.002.50
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)54.0147.8148.7647.8842.1738.7532.97
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue222184219244191273205227
Revenue growth (YoY)+16.2%-32.7%+6.8%+7.6%+5.2%---
Other income1.4015.305.7710.193.699.206.823.08
Total expenses216180214226187239189309
EBITDA6.823.405.3418.204.6833.2716.39(82.26)
EBITDA margin+3.1%+1.9%+2.4%+7.5%+2.4%+12.2%+8.0%-36.3%
Depreciation13.5113.2913.5113.4713.4013.1313.2613.44
Interest13.3822.0514.8618.7311.3417.4417.1517.92
Profit before tax(18.67)(16.64)(17.26)(3.81)(16.37)11.90(7.20)(111)
Tax(6.36)(10.99)(4.27)(0.17)(5.70)(3.72)(1.57)(37.92)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue838886773789686600580
Revenue growth-5.5%+14.6%-2.1%+15.2%+14.2%+3.5%-
Other income35.0320.6218.8828.8318.705.4724.06
Total expenses798903741656605535520
Employee cost75.9872.4866.2860.1953.3238.8728.18
EBITDA39.74(16.41)32.7213380.4465.2059.83
EBITDA margin+4.7%-1.9%+4.2%+16.9%+11.7%+10.9%+10.3%
Depreciation53.6852.5349.3932.8226.6819.2811.28
Interest75.1875.1261.8562.3936.3936.3631.33
Profit before tax(54.09)(123)(59.64)66.6236.0715.0341.28
Tax(21.13)(47.12)(8.24)19.0710.216.7410.56
Net profit(15.42)18.41(49.07)47.7325.868.5533.10
Net profit margin-1.8%+2.1%-6.4%+6.1%+3.8%+1.4%+5.7%
EPS (₹)(1.72)(4.06)(3.07)3.031.650.652.53
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital19.2118.7916.7515.7115.7012.7512.13
Reserves & surplus906840696623573403361
Shareholders' funds (net worth)929862716642592465377
Secured loans442412458535328261223
Unsecured loans39.8315.8652.9882.07132117117
Total debt482428511617461378340
Total liabilities1,4181,2961,2321,2641,056846721
Assets
Gross block756755717682381347134
Net block52656957758330429495.64
Capital work in progress22.709.1031.4428.3620718.44198
Investments21710279.8781.8081.7873.5674.02
Inventories24426325525214213197.22
Sundry debtors474414492526441368323
Cash & bank balances80.8984.6513.959.8356.4881.5913.12
Loans & advances12112999.8287.6280.9276.8177.35
Total current assets919891860876721658511
Total current liabilities354333333315279214169
Net working capital565558527561441444342
Total assets1,4181,2961,2321,2641,056846721
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash36.070.684.3522.1718.780.7018.89
Net cash from operating activities43.9618.1482.1018.5246.8026.0273.90
Net cash from investing activities(30.40)(87.66)(51.72)(115)(172)(88.00)(66.03)
Net cash from financing activities(13.41)105(34.05)78.3912980.05(26.06)
Net change in cash0.1535.39(3.67)(17.82)3.3918.08(18.19)
Closing cash80.8984.6513.959.8356.4881.5913.12
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth-5.5%+14.6%-2.1%+15.2%+14.2%+3.5%-
EBITDA growth+342.2%-150.2%-75.4%+65.3%+23.4%+9.0%-
PBT growth+56.2%-107.0%-+84.7%+140.0%-63.6%+190.9%
Net income growth-183.8%+137.5%-202.8%+84.6%+202.5%-74.2%-
Revenue CAGR (3Y)+2.0%+9.0%+8.8%+10.8%+7.7%+14.2%+21.3%
EBITDA CAGR (3Y)-33.2%--20.5%+30.5%+34.7%+103.0%+34.8%
Profitability & leverage
Net income margin-3.9%-8.6%-6.7%+6.0%+3.8%+1.4%+5.3%
Return on capital employed+2.9%+3.8%+0.2%+11.1%+7.6%+6.6%+10.5%
Return on net worth-1.7%+2.3%-7.6%+7.7%+4.9%+2.0%+8.5%
Debt / equity0.510.600.830.870.790.850.90
Long-term debt / equity0.220.270.400.460.410.340.32
Interest cover-539.31-108.96-371.0362.2867.6979.1864.53
Efficiency & per share
Fixed asset turnover1.111.201.111.491.882.494.73
Inventory turnover3.313.423.054.005.015.255.61
Debtors turnover1.891.961.521.631.701.741.98
EPS (₹)(1.72)(4.06)(3.07)3.031.650.652.53
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)48.1845.7142.5440.6737.5232.5930.80

To see the full year-wise statements and ratios of Camlin Fine Sciences Limited, buy the company report.

Board of directors of Camlin Fine Sciences Limited

Camlin Fine Sciences has 12 current directors and 20 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Ashish Subhash Dandekar
Also directs: MK Falcon Agrotech Private Limited, Abana Medisys Private Limited, Vibha Agencies Private Limited and 2 more
Managing Director11 Jan 200719 Years 9 MonthsCurrent
Nirmal Vinod Momaya
Also directs: MJ Medical Devices Private Limited, Abana Medisys Private Limited, Trucap Finance Limited and 5 more
Managing Director04 Aug 201412 Years 2 MonthsCurrent
Pradip Manilal Kanakia
Also directs: Healthcare Global Enterprises Limited, Britannia Industries Ltd, Sona BLW Precision Forgings Limited and 5 more
Director18 Oct 20215 Years 0 MonthsCurrent
Anagha Subhash Dandekar
Also directs: Camart Finance Limited, Cafco Consultants Limited
Director28 Aug 20179 Years 2 MonthsCurrent
Amol Jashvant Shah
Also directs: Anglo Gulf LLP, Organic Biosystems LLP, Fine Aromatics and Herbal Extracts Private Limited and 5 more
Director02 Aug 20197 Years 2 MonthsCurrent
Arjun Sudhakar Dukane
Also directs: Chemolutions Chemicals Limited, Naiknavare Chemicals Limited
Whole-Time Director01 Jun 20188 Years 5 MonthsCurrent
Showing 6 of 12 current directors. View all directors

Peer comparison

Camlin Fine Sciences Limited is compared with the 7 companies closest to it by revenue in the Chemicals industry (Specialty Chemicals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Kutch Chemical Industries Limited₹1,985.16 Cr (FY 2024)-33.0%New Delhi, Delhi, India
Hikal Limited₹1,864.8 Cr (FY 2025)4.0%Mumbai, Maharashtra, India
TGV Sraac Limited₹1,763.22 Cr (FY 2025)13.0%Kurnool, Andhra Pradesh, India
Camlin Fine Sciences Limitedthis company₹1,723.31 Cr (FY 2026)₹36.46 Cr2.1%5.8%612Mumbai, Maharashtra, India
Panoli Intermediates (India) Private Limited₹1,643.14 Cr (FY 2025)29.0%New Delhi, Delhi, India
Alkyl Amines Chemicals Limited₹1,601.62 Cr (FY 2025)10.0%Navi Mumbai, Maharashtra, India
Aquapharm Chemicals Private Limited₹1,571.7 Cr (FY 2024)-23.0%Pune, Maharashtra, India
Kanoria Chemicals & Industries Ltd₹1,545.92 Cr (FY 2025)3.0%Kolkata, West Bengal, India

To see the full peer comparison of Camlin Fine Sciences Limited, buy the company report.

Auditor

Camlin Fine Sciences Limited is audited by KALYANIWALLA & MISTRY LLP for the financial year 2024.

Auditor firmFinancial yearFirm registration number
KALYANIWALLA & MISTRY LLPFY 2024104607W/W100166

Shareholding

Shareholding for the quarter ended Sep 2026: promoters hold 48.00%, foreign institutional investors hold 0.90%, domestic institutional investors hold 5.40% and retail and other public shareholders hold 45.70%.

Promoters: 48.00%DII (Domestic Institutional): 5.40%FII (Foreign Institutional): 0.90%Retail & Others: 45.70%
Sep 2026
QUARTER
48.00% Promoters
5.40% DII (Domestic Institutional)
0.90% FII (Foreign Institutional)
45.70% Retail & Others
Promoter holding - history
Now 48.00% · Sep 2026High 49.10% · Dec 2025Low 48.00% · Mar 2026
47%48%49%50%51%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 49.10%Mar 2026: 48.00%Jun 2026: 48.00%Sep 2026: 48.00%49.10%48.00%48.00%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters48.00%48.00%48.00%49.10%
Public52.00%52.00%52.00%50.90%

Charges & borrowings

Open charges
₹636.6 Cr
Satisfied charges
₹1,187.59 Cr
Breakdown by lending institutions
Sbicap Trustee Company Limited₹429.00 Cr
Idbi Trusteeship Services Limited₹110.00 Cr
Others₹96.82 Cr
Hdfc Bank Limited₹0.78 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
14 Nov 2025101196871Others₹17 LakhOpen
27 Jun 2023100740681Hdfc Bank Limited₹44 LakhOpen
01 Sep 2022100613698Others₹1.65 CrOpen
21 Jul 2022100611840Others₹95 CrOpen
20 May 2022100578503Hdfc Bank Limited₹34.3 LakhOpen

To see the full charge records of Camlin Fine Sciences Limited, buy the company report.

Total charge records: 37 View all charges

Deals & funding

Camlin Fine Sciences Limited has 48 deals on record (35 market trades, 6 secondary share transfers, 4 funding rounds), with disclosed funding of ₹282.67 Cr; the latest was in April 2026.

Total deals
48
Market trades
35
Secondary share transfers
6
Funding rounds
4
QIPs
2
Disclosed funding
₹282.67 Cr

Deals on record (5 of 48)

WhenDealAmountParties
Apr 2026Market trade₹14 CrBuyer: Junomoneta Finsol Private Limited
Seller: Junomoneta Finsol Private Limited
Sep 2025Market trade₹20.01 CrBuyer: Akshat Greentech Private Limited
Jan 2025Market trade₹12.22 CrBuyer: Graviton Research Capital LLP
Seller: Graviton Research Capital LLP
Jul 2024Market trade₹52.45 CrBuyer: Graviton Research Capital LLP , Qe Securities LLP , an individual
Seller: Graviton Research Capital LLP , Qe Securities LLP , an individual
Jan 2018Market trade₹216.68 CrBuyer: Setu Securities Private Limited , Vibrant Investments, Nimi Enterprises, an individual
Seller: Setu Securities Private Limited , 3 individuals

To see the full deal history of Camlin Fine Sciences Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

Credit ratings & regulatory alerts

Camlin Fine Sciences Limited was last rated by Indiarating on 06 Jul 2021.

Rating agencyRated onRating
Indiarating06 Jul 2021

To see the full credit ratings and regulatory alerts of Camlin Fine Sciences Limited, buy the company report.

MSME payment delays

Camlin Fine Sciences Limited has 17 MSME Form 1 returns on record between 2019 and 2024, listing 1,880 overdue payments to 341 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 341)

SupplierAmount dueDue sinceReported on
Apex Techno-Plast Private Limited
an individual supplier
Adekar Enterprises Private Limited
an individual supplier
Nibatek Chemicals Private Limited

To see the full MSME payment records of Camlin Fine Sciences Limited, buy the company report.

Individuals and sole proprietors among the suppliers are not named.

Group structure & subsidiaries

Camlin Fine Sciences has 2 subsidiary companies. This group structure data is as of FY 2023. The table lists each entity with its relationship and holding.

2
Subsidiary companies
Key subsidiaries
Company NameCINShares held
Chemolutions Chemicals Ltd.U24100MH2008PLC180376
Algalr Nutrapharms Private LimitedU74900TN2014PTC096649

To see the full group structure of Camlin Fine Sciences Limited, buy the company report.

Employees & EPFO

Camlin Fine Sciences Limited has a workforce of 612 employees on its EPFO records as of Apr 09, 2024, across 2 active EPFO establishments.

Employee count
612
Active EPFO establishments
2
Employee growth
6.62%

GST

Camlin Fine Sciences has 4 GST registrations: 3 active and 1 cancelled or inactive.

Total GSTINs
4
Active
3
Cancelled / inactive
1
GSTINStateStatusRegistered on
27AACCC5235E1ZZMaharashtraActive01 Jul 2017
08AACCC5235E1ZZRajasthanActive01 Jul 2017
24AACCC5235E2Z4GujaratActive01 Sep 2017

To see the full GST registrations and return filing status of Camlin Fine Sciences Limited, buy the company report.

Recent activity

Camlin Fine Sciences Limited has 45 board changes on record since 2006: 29 appointments and 16 cessations. The latest: Jens Van Nieuwenborgh was appointed as Director on 12 Mar 2025.

Charges
A charge with Sbicap Trustee Company Limited of Rs. 429.00 Cr registered on 29 Jun 2020 with Charge ID 100352495 was modified on 28 Apr 2026.
Filing
Camlin Fine Sciences Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Mumbai I.
Charges
A charge with Others of Rs. 0.17 Cr registered on 14 Nov 2025 with Charge ID 101196871 was modified on 16 Dec 2025.
Charges
A charge with Others amounted to Rs. 0.17 Cr with Charge ID 101196871 was registered on 14 Nov 2025.
AGM
Camlin Fine Sciences Limited last Annual general meeting of members was held on 08 Aug 2025 as per latest MCA records.
Appointed
Jens Van Nieuwenborgh was appointed as Director.
Appointed
Radhika Madhukar Dudhat was appointed as Director.
Ceased
Sutapa Banerjee ceased to be Director.
Appointed
Abeezar Ebrahim Faizullabhoy was appointed as Director.
Charges
A charge registered on 17 Jul 2020 via Charge ID 100352948 with Bank Of India was fully satisfied on 03 Oct 2023.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 0.44 Cr with Charge ID 100740681 was registered on 27 Jun 2023.
Ceased
Sarvjit Singh Bedi ceased to be Director.

123 earlier events are in the company report.

News

Frequently asked questions

Camlin Fine Sciences is an active public limited company based in Mumbai, Maharashtra, India. The company works in specialty chemicals, within the chemicals and materials industry. It was incorporated on 30 November 1993 (33+ years old) and is registered under CIN L74100MH1993PLC075361. Listed on BSE: 532834 and NSE: CAMLINFINE.

Camlin Fine Sciences reported revenue of ₹1,723.31 Cr for FY 2025-26 (up 5.8% YoY) based on consolidated financials.

Camlin Fine Sciences has 12 current directors:

The latest financial statements of Camlin Fine Sciences on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 08 August 2025. Year-wise statements from 2015 are in the company report.

The GSTIN of Camlin Fine Sciences is 27AACCC5235E1ZZ, registered in Maharashtra. The company has 4 GST registrations in all, of which 3 are active and 1 is cancelled or inactive. Other active GSTINs include 08AACCC5235E1ZZ (Rajasthan), 24AACCC5235E2Z4 (Gujarat).

The CIN (Corporate Identification Number) of Camlin Fine Sciences is L74100MH1993PLC075361. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Camlin Fine Sciences is a listed company as per MCA records. Its shares are listed on both BSE (code: 532834) and NSE (symbol: CAMLINFINE).

Camlin Fine Sciences has 27 court cases on record: 14 filed by the company and 13 filed against it. 8 are pending. Most are in the high courts.

Camlin Fine Sciences was incorporated on 30 November 1993, making it 33+ years old. It is registered with the Registrar of Companies, Mumbai.

Camlin Fine Sciences has 48 deals on record (35 market trades, 6 secondary share transfers, 4 funding rounds), with disclosed funding of ₹282.67 Cr; the latest was in April 2026.

The peers of Camlin Fine Sciences by revenue are Kutch Chemical Industries Limited, Hikal Limited, TGV Sraac Limited, Panoli Intermediates (India) Private Limited, Alkyl Amines Chemicals Limited and 2 more, all in the Chemicals industry (Specialty Chemicals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).

Jens Van Nieuwenborgh was appointed as Director on 12 Mar 2025. Radhika Madhukar Dudhat was appointed as Director on 12 Mar 2025. Sutapa Banerjee ceased to be Director on 06 Feb 2025. Camlin Fine Sciences has 45 board changes on record in total.